Live Breaking News & Updates on History of public health
Stay updated with breaking news from History of public health. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share this article Share this article GUELPH, ON, and RIO DE JANEIRO, Brazil, April 6, 2021 /PRNewswire/ - PlantForm Corporation, PlantPraxis Biotecnologia and Bio-Manguinhos/Fiocruz (Health Ministry of Brazil) today announced a collaborative research and development agreement to develop a biosimilar pembrolizumab for the Brazilian market. The original antibody drug, pembrolizumab, is widely used in immunotherapy to treat a variety of cancers including melanoma, lung cancer, head and neck cancer, and stomach cancer. "This agreement advances PlantForm's collaborations in Brazil to make affordable, effective cancer drugs available to millions of Brazilians," said Dr. Don Stewart, PlantForm's President and CEO. "It also advances PlantForm's global strategy for biosimilar drug development and manufacturing to increase affordability and access to a wide range of life-saving medications."
PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world's most respected public health research institutions Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop a COVID-19 vaccine using Emergex’s next generation synthetic T-Cell vaccine technology.
News Category Global Banking & Finance Reviews Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world’s most respected public health research institutions Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop a COVID-19 vaccine using Emergex’s next generation synthetic T-Cell vaccine technology.